75860-79-6

Usage

Uses

Used in Pharmaceutical Industry:
5-METHYLTHIENO[2,3-D]PYRIMIDINE-2,4-DIOL is used as a pharmaceutical candidate for its potential anti-inflammatory properties, offering a new avenue for the treatment of inflammation-related conditions. Its structure allows it to modulate inflammatory pathways, providing a therapeutic option for various inflammatory diseases.
Used in Antiviral Applications:
In the field of antiviral research, 5-METHYLTHIENO[2,3-D]PYRIMIDINE-2,4-DIOL is utilized as a potential antiviral agent. Its unique structure may interact with viral components or host cell processes to inhibit viral replication and infection, presenting a promising direction for the development of new antiviral drugs.
Used in Organic Synthesis:
5-METHYLTHIENO[2,3-D]PYRIMIDINE-2,4-DIOL is used as a building block in organic synthesis for the creation of complex molecules. Its versatile structure allows for the formation of various derivatives, which can be further utilized in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals, broadening its applications across different industries.

InChI:InChI=1/C7H6N2O2S/c1-3-2-12-6-4(3)5(10)8-7(11)9-6/h2H,1H3,(H2,8,9,10,11)

Upstream product

• 4651-98-3 2-amino-4-methylthiophene-3-carboxylic acid methyl ester 
• 57-13-6 urea 

Downstream Products

• 56844-38-3 2,4-dichloro-5-methylthieno[2,3-d]pyrimidine 

Relevant academic research and scientific papers

Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB2R Ligands

Herein we describe the design and synthesis of a new series of heteroarylpyrimidine/heteroaryltriazine derivatives on the basis of quinazoline-2,4(1H,3H)-diones as CB2R-selective ligands using a bioisosterism strategy. An acetamide group was explored to displace the enamine linker of the lead compound for the purpose of stereoisomerism elimination and hydrophilicity increase. As a result, some of the synthesized compounds showed high bioactivity and selectivity for CB2R in calcium mobilization assays, and four displayed CB2R agonist activity, with EC50 values below 30 nm. The compound exhibiting the highest agonist activity toward CB2R (EC50=7.53±3.15 nm) had a selectivity over CB1R of more than 1328-fold. Moreover, structure–activity relationship (SAR) studies indicated that the substituents on the nucleus play key roles in the functionality of a ligand, with one such example demonstrating CB2R antagonist activity. Additionally, molecular docking simulations were conducted with the aim of better understanding of these new derivatives in relation to the structural requirements for agonists/antagonists binding to CB2R.

Heteroarylpyrimindinedione derivative and use thereof

The invention provides a heteroarylpyrimindinedione derivative and use thereof. The heteroarylpyrimindinedione derivative comprises a compound with a structure shown as general formula I, and a pharmaceutically acceptable salt or hydrate thereof. The derivative is obtained by chemical synthesis, and pharmacological experiments prove that the active ligand with cannabinoid type II receptor CB2 can be used for preparation of drugs for prevention and mitigation of CB2 receptor-mediated diseases, and the drug is cannabinoid CB2 receptor agonist's agonist, partial agonist, inverse agonist or antagonist. And the general structural formula I is shown as the specification.

ALICYCLIC HETEROCYCLIC COMPOUND

An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.